Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10007737 | 0.86 | ABL1 (0.38) | ABL1ALDH1A1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL10008048 | 0.84 | ABL1 (0.37) | ABL1ALDH1A1KDM4EHSD17B10CHRNA7 | |
| SCHEMBL10008370 | 0.84 | ABL1 (0.46) | ABL1ALDH1A1KDM4ERAB9AMAPK8 | |
| SCHEMBL10007659 | 0.83 | ABL1 (0.38) | ABL1ALDH1A1KDM4EHSD17B10CHRNA7 | |
| SCHEMBL1492340 | 0.82 | HSD17B10 (0.41) | ABL1ALDH1A1KDM4EHSD17B10CHRNA7 | |
| SCHEMBL1492397 | 0.82 | ALDH1A1 (0.41) | ABL1ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL10007777 | 0.82 | ABL1 (0.38) | ABL1ALDH1A1KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL10008122 | 0.82 | ALDH1A1 (0.41) | ABL1ALDH1A1KDM4EHSD17B10CHRNA7 | |
| SCHEMBL10007383 | 0.82 | ABL1 (0.38) | ABL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10007987 | 0.82 | ALDH1A1 (0.39) | ABL1ALDH1A1KDM4EHSD17B10CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475660-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | PRKAB1, PRKAG1, PRKAB2 | ABL1 994/4885ALDH1A1 1202/4885KDM4E 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.